Autolus Appoints Experienced Oncology Clinical Developer, Dr Vijay Peddareddigari, As Chief Medical Officer
London, 21 March 2016 – Autolus Limited (“Autolus”), a biopharmaceutical company focused on the development and commercialisation of next-generation engineered T-cell therapies for haematological and solid tumours, announced today that it has appointed Dr Vijay Peddareddigari as Chief Medical Officer.
Dr Peddareddigari brings a wealth of experience in the oncology drug development field. He started his career as a medical oncologist at MD Anderson Cancer Center (Houston, TX) before moving into the pharmaceutical industry where he initially served as Medical Director at GlaxoSmithKline. He joins Autolus from the Johnson and Johnson company, Janssen Pharmaceuticals Inc., where he served as Senior Director & Clinical Leader, Early Development. Until January 2016, he also held a position as Adjunct Assistant Professor of Medicine, Division of Haematology/Oncology at the University of Pennsylvania.
Dr Christian Itin, Chief Executive Officer of Autolus, said:
“We are delighted to welcome Vijay to Autolus as Chief Medical Officer. He has a proven track record in clinical development and over the past six years has brought eight molecules, including a first-in-class immuno-oncology asset, to the clinic, as well as one to the market; experience that will be invaluable as we prepare to initiate our first clinical studies.”
Dr Vijay Peddareddigari, Chief Medical Officer of Autolus, added:
“It’s an exciting time for this area of cancer therapy. The team at Autolus have differentiated themselves with a unique technology base and differentiated product candidates and I believe we are well-positioned to bring real benefits to patients with both haematological and solid tumours.”
Autolus is founded upon the work of Dr Martin Pule, an academic clinical haematologist at University College London and a thought-leader in T-cell engineering. It is a next-generation engineered T-cell company, developing a series of T-cell products based on its proprietary targets, constructs and technologies.
– Ends –
Further information:
JW Communications
Julia Wilson
+44 (0)7818 430877
juliawilsonuk@gmail.com
Notes for Editors:
About Autolus
Autolus is a private biopharmaceutical company, focused on the development and commercialisation of engineered T-cell immunotherapy products based on its proprietary T-cell programming technology. Autolus’ shareholders include Syncona LLP, UCL Business PLC, Woodford Investment Management LLP and Perceptive Bioscience Investments Ltd. For further information please visit the Company’s website at: www.autolus.com
Dr Peddareddigari brings a wealth of experience in the oncology drug development field. He started his career as a medical oncologist at MD Anderson Cancer Center (Houston, TX) before moving into the pharmaceutical industry where he initially served as Medical Director at GlaxoSmithKline. He joins Autolus from the Johnson and Johnson company, Janssen Pharmaceuticals Inc., where he served as Senior Director & Clinical Leader, Early Development. Until January 2016, he also held a position as Adjunct Assistant Professor of Medicine, Division of Haematology/Oncology at the University of Pennsylvania.
Dr Christian Itin, Chief Executive Officer of Autolus, said:
“We are delighted to welcome Vijay to Autolus as Chief Medical Officer. He has a proven track record in clinical development and over the past six years has brought eight molecules, including a first-in-class immuno-oncology asset, to the clinic, as well as one to the market; experience that will be invaluable as we prepare to initiate our first clinical studies.”
Dr Vijay Peddareddigari, Chief Medical Officer of Autolus, added:
“It’s an exciting time for this area of cancer therapy. The team at Autolus have differentiated themselves with a unique technology base and differentiated product candidates and I believe we are well-positioned to bring real benefits to patients with both haematological and solid tumours.”
Autolus is founded upon the work of Dr Martin Pule, an academic clinical haematologist at University College London and a thought-leader in T-cell engineering. It is a next-generation engineered T-cell company, developing a series of T-cell products based on its proprietary targets, constructs and technologies.
– Ends –
Further information:
JW Communications
Julia Wilson
+44 (0)7818 430877
juliawilsonuk@gmail.com
Notes for Editors:
About Autolus
Autolus is a private biopharmaceutical company, focused on the development and commercialisation of engineered T-cell immunotherapy products based on its proprietary T-cell programming technology. Autolus’ shareholders include Syncona LLP, UCL Business PLC, Woodford Investment Management LLP and Perceptive Bioscience Investments Ltd. For further information please visit the Company’s website at: www.autolus.com